Florida's bioRASI has completed its acquisition of Sponsors Clinical Research Group, planning to integrate the Ukraine company's capabilities and client roster into its growing Eastern European market share.
India's struggles to regulate its booming clinical research industry are well told, but now China could be headed down the same path, as a Beijing court has taken issue with how trial-runners pay compensation to patients.
Shares of Repros Therapeutics rocketed up 78% this morning after the Texas-based biotech announced that its roller coaster ride in a Phase III study for its experimental testosterone-boosting therapy Androxal ended on a positive note on a pair of co-primary endpoints.
After a quick review, new CEO Nick Colangelo and his team have taken bold actions to set a new course for Aastrom Biosciences. The Ann Arbor, MI-based biotech has slammed the brakes on a Phase III study of its lead cellular therapy for critical limb ischemia.
The clock is ticking for Sarepta, a multitude of biotech investors and the boys who suffer from Duchenne muscular dystrophy.
When the early-stage CRO PRACS Institute filed for Chapter 7 bankruptcy late last week, suddenly dismissing hundreds of workers and leaving their trial subjects unpaid, the company left a Who's Who of the biopharma industry on its list of creditors as dozens of trials suddenly ground to a halt, unfinished.
The company didn't spell out the data, but it made clear that the drug failed to hit the primary endpoint of progression-free survival--prompting executives to call for the budget ax.
More and more research universities are jumping into the CRO game, using their existing labs and expertise to launch moneymaking operations. Duke University's clinical research unit has signed on with Benitec Biopharma to run Phase I/II trials for an RNAi hepatitis C drug.
Genzyme executives today rolled out positive data from a one-year extension study of its pivotal Phase III trial that gives the company some boasting rights for a drug that demonstrated a durable response in most patients.
Shares of San Diego-based Acadia Pharmaceuticals surged 28% this morning after the biotech spelled out some of its Phase III data on pimavanserin, its experimental therapy for treating psychosis in Parkinson's patients.